Review: Pharmacodynamic monitoring of immunosuppression in kidney transplantation

Nephrology

Volumn 15, Issue 5, 2010, Pages 522-532

  Barraclough, Katherine A ^a   Staatz, Christine E ^a   Isbel, Nicole M ^a   McTaggart, Steven J ^a,b  

^a UNIVERSITY OF QUEENSLAND   (Australia)

^b MATER MEDICAL RESEARCH INSTITUTE   (Australia)

Author keywords

immune function marker; immunosuppressant therapy; kidney transplantation; pharmacodynamic monitoring

Indexed keywords

ADENOSINE TRIPHOSPHATE; AZATHIOPRINE; CD30 ANTIGEN; CYCLOSPORIN A; GAMMA INTERFERON; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 10; INTERLEUKIN 2; MESSENGER RNA; MYCOPHENOLIC ACID; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISOLONE; TACROLIMUS; TUMOR NECROSIS FACTOR ALPHA; BIOLOGICAL MARKER; IMMUNOSUPPRESSIVE AGENT;

CELL FUNCTION; CYTOKINE PRODUCTION; ENZYME LINKED IMMUNOSORBENT ASSAY; ENZYME LINKED IMMUNOSPOT ASSAY; EX VIVO STUDY; FLUORESCENCE ACTIVATED CELL SORTING; HUMAN; IMMUNE FUNCTION TEST; IMMUNOCOMPETENT CELL; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY TRANSPLANTATION; LYMPHOCYTE PROLIFERATION; METHODOLOGY; NONHUMAN; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; REVIEW; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; ANIMAL; DRUG EFFECTS; DRUG MONITORING; GRAFT REJECTION; GRAFT SURVIVAL; IMMUNOLOGICAL MONITORING; IMMUNOLOGY; LYMPHOCYTE ACTIVATION; METABOLISM; PERSONALIZED MEDICINE; PREDICTIVE VALUE; PROCEDURES; T LYMPHOCYTE SUBPOPULATION; TREATMENT OUTCOME;

ANIMALS; BIOLOGICAL MARKERS; DRUG MONITORING; GRAFT REJECTION; GRAFT SURVIVAL; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INDIVIDUALIZED MEDICINE; KIDNEY TRANSPLANTATION; LYMPHOCYTE ACTIVATION; MONITORING, IMMUNOLOGIC; PREDICTIVE VALUE OF TESTS; T-LYMPHOCYTE SUBSETS; TREATMENT OUTCOME;

EID: 77955076142     PISSN: 13205358     EISSN: 14401797     Source Type: Journal    
DOI: 10.1111/j.1440-1797.2010.01349.x     Document Type: Review

References (60)

1. Meier-Kriesche HU, Schold JD, Srinivas TR, Kaplan B. Lack of improvement in renal allograft survival despite a marked decrease in acute rejection rates over the most recent era. Am. J. Transplant. 2004 4 : 378 383.
2. Chang SH, Russ GR, Chadban SJ, Campbell SB, McDonald SP. Trends in kidney transplantation in Australia and New Zealand, 1993-2004. Transplantation 2007 84 : 611 618.
3. US Renal Data System. USRDS Annual Data Report: Atlas of End-Stage Renal Disease in the United States.
4. Ashton-Chess J, Giral M, Soulillou JP, Brouard S. Can immune monitoring help to minimize immunosuppression in kidney transplantation? Transpl. Int. 2009 22 : 110 119.
5. Rostaing L, Puyoo O, Tkaczuk J et al. Differences in Type 1 and Type 2 intracytoplasmic cytokines, detected by flow cytometry, according to immunosuppression (cyclosporine A vs. tacrolimus) in stable renal allograft recipients. Clin. Transplant. 1999 13 : 400 409.
6. Stalder M, Birsan T, Holm B, Haririfar M, Scandling J, Morris RE. Quantification of immunosuppression by flow cytometry in stable renal transplant recipients. Ther. Drug Monit. 2003 25 : 22 7.
7. Weimer R, Zipperle S, Daniel V, Carl S, Staehler G, Opelz G. Pretransplant CD4 helper function and interleukin 10 response predict risk of acute kidney graft rejection. Transplantation 1996 62 : 1606 1614.
8. Couzi L, Thiebaut R, Carron JC, Moreau JF, Merville P, Taupin JL. Immunological monitoring of calcineurin inhibitors for predicting cytomegalovirus infection in kidney transplant recipients. Transplantation 2008 86 : 1060 1067.
9. Bohler T, Canivet C, Nguyen PN et al. Cytokines correlate with age in healthy volunteers, dialysis patients and kidney-transplant patients. Cytokine 2009 45 : 169 173.
10. Kamar N, Glander P, Nolting J et al. Pharmacodynamic evaluation of the first dose of mycophenolate mofetil before kidney transplantation. Clin. J. Am. Soc. Nephrol. 2009 4 : 936 942.
11. Weimer R, Melk A, Daniel V, Friemann S, Padberg W, Opelz G. Switch from cyclosporine A to tacrolimus in renal transplant recipients: Impact on Th1, Th2, and monokine responses. Hum. Immunol. 2000 61 : 884 897.
12. Blazik M, Hutchinson P, Jose MD et al. Leukocyte phenotype and function predicts infection risk in renal transplant recipients. Nephrol. Dial. Transplant. 2005 20 : 2226 2230.
13. Stein CM, Murray JJ, Wood AJ. Inhibition of stimulated interleukin-2 production in whole blood: A practical measure of cyclosporine effect. Clin. Chem. 1999 45 : 1477 1484.
14. Millan O, Brunet M, Campistol JM et al. Pharmacodynamic approach to immunosuppressive therapies using calcineurin inhibitors and mycophenolate mofetil. Clin. Chem. 2003 49 : 1891 1899.
15. Grinyo JM, Cruzado JM, Millan O et al. Low-dose cyclosporine with mycophenolate mofetil induces similar calcineurin activity and cytokine inhibition as does standard-dose cyclosporine in stable renal allografts. Transplantation 2004 78 : 1400 1403.
16. Tary-Lehmann M, Hricik DE, Justice AC, Potter NS, Heeger PS. Enzyme-linked immunosorbent assay spot detection of interferon-gamma and interleukin 5-producing cells as a predictive marker for renal allograft failure. Transplantation 1998 66 : 219 224.
17. Hartel C, Fricke L, Schumacher N, Kirchner H, Muller-Steinhardt M. Delayed cytokine mRNA expression kinetics after T-lymphocyte costimulation: A quantitative measure of the efficacy of cyclosporin A-based immunosuppression. Clin. Chem. 2002 48 : 2225 2231.
18. Hartel C, Schumacher N, Fricke L, Ebel B, Kirchner H, Muller-Steinhardt M. Sensitivity of whole-blood T lymphocytes in individual patients to tacrolimus (FK 506): Impact of interleukin-2 mRNA expression as surrogate measure of immunosuppressive effect. Clin. Chem. 2004 50 : 141 151.
19. Giese T, Zeier M, Schemmer P et al. Monitoring of NFAT-regulated gene expression in the peripheral blood of allograft recipients: A novel perspective toward individually optimized drug doses of cyclosporine A. Transplantation 2004 77 : 339 344.
20. Sommerer C, Konstandin M, Dengler T et al. Pharmacodynamic monitoring of cyclosporine a in renal allograft recipients shows a quantitative relationship between immunosuppression and the occurrence of recurrent infections and malignancies. Transplantation 2006 82 : 1280 1285.
21. Wang D, Wu GJ, Wu WZ et al. Pre- and post-transplant monitoring of soluble CD30 levels as predictor of acute renal allograft rejection. Transpl. Immunol. 2007 17 : 278 282.
22. Susal C, Pelzl S, Dohler B, Opelz G. Identification of highly responsive kidney transplant recipients using pretransplant soluble CD30. J. Am. Soc. Nephrol. 2002 13 : 1650 1656.
23. Cinti P, Pretagostini R, Arpino A et al. Evaluation of pretransplant immunologic status in kidney-transplant recipients by panel reactive antibody and soluble CD30 determinations. Transplantation 2005 79 : 1154 1156. (Pubitemid 40664014)
24. Pelzl S, Opelz G, Wiesel M et al. Soluble CD30 as a predictor of kidney graft outcome. Transplantation 2002 73 : 3 6.
25. Kim MS, Kim HJ, Kim SI et al. Pretransplant soluble CD30 level has limited effect on acute rejection, but affects graft function in living donor kidney transplantation. Transplantation 2006 82 : 1602 1605.
26. Truong DQ, Darwish AA, Gras J et al. Immunological monitoring after organ transplantation: Potential role of soluble CD30 blood level measurement. Transpl. Immunol. 2007 17 : 283 287.
27. Dong W, Shunliang Y, Weizhen W et al. Prediction of acute renal allograft rejection in early post-transplantation period by soluble CD30. Transpl. Immunol. 2006 16 : 41 5.
28. Weimer R, Susal C, Yildiz S et al. Post-transplant sCD30 and neopterin as predictors of chronic allograft nephropathy: Impact of different immunosuppressive regimens. Am. J. Transplant. 2006 6 : 1865 1874.
29. Spiridon C, Nikaein A, Lerman M, Hunt J, Dickerman R, Mack M. CD30, a marker to detect the high-risk kidney transplant recipients. Clin. Transplant. 2008 22 : 765 769.
30. Pelzl S, Opelz G, Daniel V, Wiesel M, Susal C. Evaluation of posttransplantation soluble CD30 for diagnosis of acute renal allograft rejection. Transplantation 2003 75 : 421 423.
31. Kowalski R, Post D, Schneider MC et al. Immune cell function testing: An adjunct to therapeutic drug monitoring in transplant patient management. Clin. Transplant. 2003 17 : 77 88.
32. Cadillo-Chavez R, de Echegaray S, Santiago-Delpin EA et al. Assessing the risk of infection and rejection in Hispanic renal transplant recipients by means of an adenosine triphosphate release assay. Transplant. Proc. 2006 38 : 918 920.
33. Reinsmoen NL, Cornett KM, Kloehn R et al. Pretransplant donor-specific and non-specific immune parameters associated with early acute rejection. Transplantation 2008 85 : 462 470.
34. Kowalski RJ, Post DR, Mannon RB et al. Assessing relative risks of infection and rejection: A meta-analysis using an immune function assay. Transplantation 2006 82 : 663 668.
35. Batal I, Zeevi A, Heider A et al. Measurements of global cell-mediated immunity in renal transplant recipients with BK virus reactivation. Am. J. Clin. Pathol. 2008 129 : 587 591.
36. Najafian N, Albin MJ, Newell KA. How can we measure immunologic tolerance in humans? J. Am. Soc. Nephrol. 2006 17 : 2652 2663.
37. Segundo DS, Ruiz JC, Izquierdo M et al. Calcineurin inhibitors, but not rapamycin, reduce percentages of CD4+CD25+FOXP3+ regulatory T cells in renal transplant recipients. Transplantation 2006 82 : 550 557.
38. Braudeau C, Racape M, Giral M et al. Variation in numbers of CD4+CD25highFOXP3+ T cells with normal immuno-regulatory properties in long-term graft outcome. Transpl. Int. 2007 20 : 845 855.
39. Louis S, Braudeau C, Giral M et al. Contrasting CD25hiCD4+T cells/FOXP3 patterns in chronic rejection and operational drug-free tolerance. Transplantation 2006 81 : 398 407.
40. Bunnag S, Allanach K, Jhangri GS et al. FOXP3 expression in human kidney transplant biopsies is associated with rejection and time post transplant but not with favorable outcomes. Am. J. Transplant. 2008 8 : 1423 1433.
41. Muthukumar T, Dadhania D, Ding R et al. Messenger RNA for FOXP3 in the urine of renal-allograft recipients. N. Engl. J. Med. 2005 353 : 2342 2351.
42. Cortesini R, Renna-Molajoni E, Cinti P et al. Tailoring of immunosuppression in renal and liver allograft recipients displaying donor specific T-suppressor cells. Hum. Immunol. 2002 63 : 1010 1018.
43. Chang DM, Ding YA, Kuo SY, Chang ML, Wei J. Cytokines and cell surface markers in prediction of cardiac allograft rejection. Immunol. Invest. 1996 25 : 13 21.
44. Jordan SC, Czer L, Toyoda M et al. Serum cytokine levels in heart allograft recipients: Correlation with findings on endomyocardial biopsy. J. Heart Lung Transplant. 1993 12 : 333 337.
45. Grant SC, Lamb WR, Brooks NH, Brenchley PE, Hutchinson IV. Serum cytokines in human heart transplant recipients. Is there a relationship to rejection? Transplantation 1996 62 : 480 491.
46. Fyfe A, Daly P, Galligan L, Pirc L, Feindel C, Cardella C. Coronary sinus sampling of cytokines after heart transplantation: Evidence for macrophage activation and interleukin-4 production within the graft. J. Am. Coll. Cardiol. 1993 21 : 171 176.
47. Kutukculer N, Clark K, Rigg KM et al. The value of posttransplant monitoring of interleukin (IL)-2, IL-3, IL-4, IL-6, IL-8, and soluble CD23 in the plasma of renal allograft recipients. Transplantation 1995 59 : 333 340.
48. Chollet-Martin S, Depoix JP, Hvass U, Pansard Y, Vissuzaine C, Gougerot-Pocidalo MA. Raised plasma levels of tumor necrosis factor in heart allograft rejection. Transplant. Proc. 1990 22 : 283 286.
49. Kita Y, Iwaki Y, Demetris AJ, Starzl TE. Evaluation of sequential serum interleukin-6 levels in liver allograft recipients. Transplantation 1994 57 : 1037 1041.
50. Schmittel A, Keilholz U, Scheibenbogen C. Evaluation of the interferon-gamma ELISPOT-assay for quantification of peptide specific T lymphocytes from peripheral blood. J. Immunol. Methods 1997 210 : 167 174.
51. Karlsson AC, Martin JN, Younger SR et al. Comparison of the ELISPOT and cytokine flow cytometry assays for the enumeration of antigen-specific T cells. J. Immunol. Methods 2003 283 : 141 153.
52. Orlando G, Soker S, Wood K. Operational tolerance after liver transplantation. J. Hepatol. 2009 50 : 1247 1257.
53. Goodstadt L, Ponting CP. Sequence variation and disease in the wake of the draft human genome. Hum. Mol. Genet. 2001 10 : 2209 2214.
54. Khatri P, Sarwal MM. Using gene arrays in diagnosis of rejection. Curr. Opin. Organ Transplant. 2009 14 : 34 9.
55. Nath DS, Basha HI, Mohanakumar T. Antihuman leukocyte antigen antibody-induced autoimmunity: Role in chronic rejection. Curr. Opin. Organ Transplant. 2010 15 : 16 20.
56. Slavcev A, Lacha J, Honsova E et al. Soluble CD30 and HLA antibodies as potential risk factors for kidney transplant rejection. Transpl. Immunol. 2005 14 : 117 121.
57. Sengul S, Keven K, Gormez U, Kutlay S, Erturk S, Erbay B. Identification of patients at risk of acute rejection by pretransplantation and posttransplantation monitoring of soluble CD30 levels in kidney transplantation. Transplantation 2006 81 : 1216 1219.
58. United States Department of Health and Human Services. K013169. Cyclex Immune Cell Function Assay. 2 April 2002.
59. Ding R, Li B, Muthukumar T et al. CD103 mRNA levels in urinary cells predict acute rejection of renal allografts. Transplantation 2003 75 : 1307 1312.
60. Tatapudi RR, Muthukumar T, Dadhania D et al. Noninvasive detection of renal allograft inflammation by measurements of mRNA for IP-10 and CXCR3 in urine. Kidney Int. 2004 65 : 2390 2397.